Recent Press Releases

Cubist Announces FDA Approval of New Antibiotic ZERBAXA(TM) (Ceftolozane/Tazobactam) for Complicated Urinary Tract and Complicated Intra-abdominal Infections

ZERBAXA addresses certain serious and resistant Gram-negative bacteria First new antibiotic approved in U.S. under the GAIN Act that treats Gram-negative bacteria LEXINGTON, Mass. - (Business...

FDA approves Lynparza to treat advanced ovarian cancer

The U.S. Food and Drug Administration today granted accelerated approval to Lynparza (olaparib), a new drug treatment for women with advanced ovarian cancer associated with defective BRCA genes, as...

LYNPARZA™ APPROVED BY THE US FOOD AND DRUG ADMINISTRATION FOR THE TREATMENT OF ADVANCED OVARIAN CANCER IN PATIENTS WITH GERMLINE BRCA-MUTATIONS

19 December 2014 AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved LYNPARZA™ (olaparib) capsules (400mg twice daily) as the first monotherapy for patients...

Bina Technologies is acquired by Roche.

REDWOOD CITY, Calif., Dec. 19, 2014 /PRNewswire/ -- Bina Technologies, Inc.

Teva Announces FDA Approval of QNASL® (Beclomethasone Dipropionate) Nasal Aerosol for Treatment of Children with Seasonal and Perennial Allergic Rhinitis

First Waterless Nasal Allergy Spray Approved for Children as Young as Four Years of Age JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (TEVJF), (NYSE:TEVA) announced today that the...

Orexigen's Mysimba™ (naltrexone HCl / bupropion HCl prolonged release) Receives Positive CHMP Opinion Recommending Approval for Weight Management in the European Union

LA JOLLA, Calif., Dec. 19, 2014 /PRNewswire/ -- Orexigen Therapeutics (NASDAQ: OREX) announced today that the Committee for Medicinal Products For Human Use (CHMP) of the European Medicines Agency...

Roche provides update on Phase III MARIANNE study in people with previously untreated advanced HER2-positive breast cancer

Roche provides update on Phase III MARIANNE study in people with previously untreated advanced HER2-positive breast cancer MARIANNE was designed to evaluate three HER2-targeted regimens in previously...

Abbott to Present at J.P. Morgan Healthcare Conference

ABBOTT PARK, Ill., Dec. 18, 2014 /PRNewswire/ -- Abbott (NYSE: ABT) will present at the 33rd Annual J.P.

14 Indicted in Connection with New England Compounding Center and Nationwide Fungal Meningitis Outbreak

WASHINGTON – A 131-count criminal indictment was unsealed today in Boston in connection with the 2012 nationwide fungal meningitis outbreak, the Justice Department announced. Barry J. Cadden,...

Lynparza™approved in the European Union as first-in-class treatment for advanced BRCA-mutated ovarian cancer

Lynparza™approved in the European Union as first-in-class treatment for advanced BRCA-mutated ovarian cancer Thursday, 18 December 2014 AstraZeneca today announced that the European Commission...

Amgen Announces 30 Percent Increase In 2015 First Quarter Dividend

THOUSAND OAKS, Calif., Dec.

NICE proposes to recommend a new treatment for some people with advanced kidney cancer

NICE, the healthcare guidance body, has issued new final draft guidance recommending axitinib (Inlyta, Pfizer), for advanced kidney cancer [1]. Renal cell carcinoma is a kidney cancer that starts in...

NICE recommends dabigatran (Pradaxa) for treating and preventing potentially fatal blood clots

In final guidance published today (17 December 2014) NICE has recommended the anti-blood clotting drug dabigatran (Pradaxa, Boehringer Ingelheim) as an option for treating and preventing recurrent...

UCB, Advent International and Avista Capital Partners mutually agree to terminate acquisition agreement for Kremers Urban

UCB, Advent International and Avista Capital Partners mutually agree to terminate acquisition agreement for Kremers Urban Mutual agreement driven by conflicting timing for the acquisition (including...

Valeant Pharmaceuticals To Hold Conference Call To Announce 2015 Financial Guidance

LAVAL, Quebec, Dec. 15, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it will host a conference call and a live Internet webcast along...

Sucampo Appoints John H. Johnson to Board of Directors

BETHESDA, Md., Dec. 15, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced the appointment of John H. Johnson,...

Salix Pharmaceuticals Provides Updates on Wholesaler Inventory Reductions and the XIFAXAN® 550 for IBS-D Approval Timeline, and Provides Preliminary Guidance for 2015 and 2016

Expects to Achieve Wholesale Inventory Targets by Year End 2015 Announces Extension of PDUFA Action Date for XIFAXAN® 550 for IBS-D to May 27 Provides Preliminary Guidance for Full Years...

Novartis announces results of trial evaluating the use of Afinitor® in first-line treatment in HER2+ advanced breast cancer at SABCS

Basel, December 12, 2014 - Novartis today announced results of the BOLERO-1 (Breast cancer trials of OraL EveROlimus-1) trial of Afinitor® (everolimus) tablets in combination with trastuzumab...